Facilitated subcutaneous immunoglobulin 10% at a target dose of 0.4 g/kg/infusion is well tolerated with accelerated or no dose ramp-up in healthy participants
Zhaoyang Li(Yangpu Hospital of Tongji University), Leman Yel(Children's Hospital of Philadelphia), Noor M. Khaskhely(Takeda (United States)), Kimberly Duff(Takeda (United States)), Juan Carlos Rondón(Clinical Pharmacology of Miami), Dirk Lindner(Takeda (United States)), András Nagy(University of Szeged), Enrique García(Takeda (United States)), Hakan Ay(Takeda (United States))
Cited by 1
Related Papers
A Comprehensive Overview on Chemotherapy-Induced Cardiotoxicity: Insights into the Underlying Inflammatory and Oxidative Mechanisms
|Cardiovascular Drugs and Therapy|2024|38
Selected Abstracts from the 12th Annual Meeting of the Clinical Immunology Society: 2021 Virtual Annual Meeting: Immune Deficiency and Dysregulation North American Conference
|Journal of Clinical Immunology|2021|28
Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study
|Immunotherapy|2024|5
Vitamin D and breast cancer
|Orvosi Hetilap|2014|4